Abstract Background: Medulloblastomas are the most common primary malignant childhood intracranial neoplasms. Patients are currently sorted into three risk groups based on clinical criteria: standard, poor, and infant (<18 months old).We hypothesized that genetic copy number aberrations (CNA) predict prognosis and would provide improved criteria for predicting outcome. Methods: DNA from 35 medulloblastoma patients from four Children's Cancer Group trials was analyzed by comparative genomic hybridization to determine CNAs. The genetic alterations were evaluated using statistical and cluster analyses. Results:The most frequent CNAs were gains on17q, 7, 1q, and 7q and losses on 17p, 10q, X, 16q, and 11q. Amplification at 5p15.1-p15.3 was also detected. Isochromosome 17q (i(17)(q10)) was associated with poor overall survival (P = 0.03) and event-free survival (P = 0.04) independent of poor risk group classification. Age <3 tended to be associated with <3 CNAs (P = 0.06). Unsupervised cluster analysis sorted the study patients into four subgroups based on CNAs. Supervised analysis using the program Significance Analysis of Microarrays (SAM) quantitatively validated those CNAs identified by unsupervised clustering that significantly distinguished among the four subgroups. Conclusions: Medulloblastomas are genetically heterogeneous and can be categorized into separate genetic subgroups by their CNAs using unsupervised cluster analysis and SAM. i(17)(q10) was a significant independent negative prognostic factor. Infant medulloblastomas may be a distinct genetic subset from those of older patients.
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Medulloblastoma is the most common pediatric primary malignant intracranial neoplasm, accounting for 25% of all childhood tumors (1) . Despite its sensitivity to chemotherapy and radiation therapy, the 5-year survival rate is f50% to 60% (2) . Medulloblastomas can be graded, with good correlation between grade and outcome (3, 4) . Therapeutic regimens are based on clinical prognostic factors such as age at diagnosis, extent of residual disease after resection, and the presence or absence of disseminated disease. Patients older than 3 years with minimal or no residual disease after surgery and no evidence of dissemination are considered standard risk. Those younger than 3 years, with subtotal resections, or with disseminated disease at diagnosis are poor risk. The 5-year survival rates are f70% for standard-risk and 40% for poor-risk patients (2) . Outcomes for infants ages <18 months are even worse; their 3-year progression-free survival is only 22% (5) .
Clinical factors do not predict accurately which standard-risk patients will have early relapses and die. Biological factors, such as elevated TrkC (6) or elevated c-MYC mRNA expression (7) have been correlated with improved and worse survival, respectively. Pomeroy et al. recently reported a multigene predictor based on gene expression profiles that could accurately identify standard-risk medulloblastoma patients with poor clinical outcomes (8) . Therefore, we hypothesized that specific genetic alterations are associated with outcome. To test this hypothesis, we analyzed 35 medulloblastoma samples using comparative genomic hybridization (CGH) to detect tumor DNA copy number aberrations (CNA) and correlated the results with patient survival. CGH detects the relative copy number of genetic material by comparing hybridizations of reference and tumor DNA with those of normal metaphase chromosomes (9) . Our study goals were to determine whether there were correlations between medulloblastoma CNAs and outcome and use them to develop a more accurate medulloblastoma grading system based on genetic criteria.
Materials and Methods
DNA preparation and labeling. Paraffin sections from the Brain Tumor Resource Laboratory of the Children's Cancer Group were deparaffinized by xylene treatment. Standard DNA extraction protocol was applied using a Puregene DNA isolation kit (Gentra Systems, Minneapolis, MN). Normal male and female reference DNA was prepared in the same manner from donor mononuclear cells. Tumor and normal DNA were labeled with fluoroscein-10-dUTP and Texas Red-dUTP (DuPont, Wilmington, DE), respectively, by nick translation using DNase I and Polymerase I from Life Technologies (Carlsbad, CA; ref. 10). Distribution of probe fragment size ranged from 200 to 1,300 bp and the bulk of DNA ranged from 300 to 800 bp. Samples that did not yield enough DNA for nick translation were amplified by degenerate oligonucleotide primer PCR (11) . In such cases, the tumor and normal DNA were labeled with digoxygenin-dUTP (Roche, Indianapolis, IN) and FITC-dUTP (DuPont), respectively.
Comparative genomic hybridization. CGH was done according to a previous protocol (10) using 400 ng each of labeled tumor and reference DNA. If degenerate oligonucleotide primer PCR -labeled probes were used for hybridization, the metaphase spreads were incubated first in blocking buffer at room temperature for 5 minutes, then with 1 Ag/mL rhodamine-conjugated anti-Dig-antibody (Roche) in blocking buffer at room temperature for 45 minutes. Subsequently, the slides were washed and counterstained with 4V,6-diamidino-2-phenylindole. Red, green, and blue images were acquired with a Quantitative Image Processing System, and the ratios of fluorescence intensity along the chromosomes were quantified as described (12) .
Statistical methods. We analyzed relationships between clinical variables and CNAs. The primary end points were event-free survival (EFS) and overall survival (OS). EFS was the minimum time from entry to disease progression, second malignant neoplasm, or death from any cause; OS was determined from entry to death from any cause. Nonparametric estimates of EFS and OS probabilities were calculated by the product limit (Kaplan-Meier) estimate, with the SEs computed by the Greenwood formula (13) . Estimates are presented as estimate F SE. Comparisons of outcome were based on the log-rank test and exact log-rank tests from StatXact (Cytel Software Corp, Cambridge, MA). Stratified log-rank tests also were done to adjust for potential prognostic factors. Comparisons of frequency counts were based on two-sided Fisher exact test and m 2 tests, as appropriate (14) . The three patients designated as lost to follow-up did not have continued data forms for follow-up at last contact. All three patients were alive at last contact >5 years from entry date and thus were classified as alive for statistical analysis.
A two-dimensional hierarchical clustering analysis was used to identify groups of patients with similar chromosomal aberrations and common chromosomal aberrations across all cases (15) . Uncentered correlation metric and average linkage were used for both dimensions. The relative gains and losses for each chromosome band of all the chromosomes were noted and converted to annotated designations of 0 (no change), +1 (gain), À1 (loss), and +2 (amplification) in chromosomal copy number before clustering.
We used the program Significance Analysis of Microarrays (SAM) to correlate chromosomal aberrations with risk groups, M stage, and gender (16) . The percentage of CNAs identified as significant by chance is the False Discovery Rate (FDR). The significance of an aberration is reported as the q value, which is the lowest FDR at which the aberration is designated as significant. We ran SAM using two-class unpaired data analysis with 1,000 permutations. The delta scale was adjusted such that the median number of false significant aberrations was <1.0 and a list of significant CNAs was generated. Those chromosomal bands with qs < 5% were designated as significant.
Case selection. Medulloblastoma cases from the Children's Cancer Group (CCG) protocols were reviewed centrally before inclusion. Initially, 41 cases from five CCG protocols, including protocols accepting patients with tumors other than medulloblastoma, were accepted and analyzed by CGH. Neuropathologists were blinded to original diagnoses and CGH molecular findings. Based on the reviews, three cases were diagnosed as ependymomas, two were atypical rhabdoid tumors, and one had no tumor on the slide and thus could not be histologically verified as medulloblastoma. Genetic changes in these six cases were not characteristic of medulloblastomas. These six cases were excluded based on genetic and histologic analyses, leaving 35 cases in our study. Five of the six excluded cases were from CCG 9921, leaving cases from only four CCG studies (921, 923, 9892, and 9931).
Results
Clinical characteristics. The demographic characteristics of the 35 medulloblastoma patients are summarized in Table 1 . The median age at study entry was 6.3 years (range, 0.6-14.9 years), there was male predominance, and the distribution of age and M stage was unremarkable. The median number of days on study was 2,696 (range, 48-5,368 days). There was no effect of the various treatment regimens on survival and no significant difference in OS among the four CCG studies (P = 0.78). Five-year OS rates for the four studies were 60 F 13% for CCG 921, 75 F 15% for 923, 60 F 22% for 9892, and 57 F 19% for 9931. Thus, differences in outcome among the study patients were not likely due to treatment regimens or selection bias. The clinical and genetic characteristics of the medulloblastoma patients and their tumors are listed in Table 2 .
The median survival of the 35 study patients was 12.6 years. The median survival among patients who died was 482 days (range, 48-4,619 days). Eleven patients (31%) developed progressive disease; the median number of days to recurrence Figure 1 shows the OS of study patients by risk group. Five-year OS and EFS rates for various demographic factors are listed in Table 3 . As expected, improved OS and EFS rates were associated with M 0 stage and standard-risk group classification. Neither residual tumor amount nor patient gender influenced OS or EFS. Older age at diagnosis (z3) was nearly significantly associated with improved OS and EFS. The data suggests that our patients were a reasonable representation of medulloblastoma patients in general.
Copy number aberrations. CNAs in the 35 medulloblastomas are summarized in Fig. 2 . The median number of CNAs per tumor was 4 (range, 0-12). There was no association between number of CNAs (<3 versus z3) and OS (P = 0.71) or EFS (P = 0.70). The most frequent losses occurred on chromosomes 17p (29%), 10q (23%), X (20%), 16q (17%), and 11q (17%). The most frequent gains occurred on chromosomes 17q (34%), 7 (23%), 7q (14%), and 1q (14%). Amplification was detected at 5p15.1-p15.3 in one patient. Loss of chromosome 17p along with gain of 17q, which is suggestive of an isochromosome 17q (i(17)(q10)), occurred in 5 of 35 patients (14%).
Individual chromosomal bands with aberrations that occurred in z4 tumors were analyzed for potential correlations with OS and EFS (Table 4) . i(17)(q10) was associated with decreased OS (P = 0.03) and EFS (P = 0.04). The 5-year OS rate was f70 F 8% for patients without i(17)(q10) compared with only 20 F 18% for those with i(17)(q10). In addition, À9q tended to be associated with improved OS (P = 0.07) and EFS (P= 0.07), as all five patients with À9q were alive at last contact. Some CNAs were associated with demographic characteristics, such as ÀX with female gender (P = 0.001), and À10q (P = 0.024), and À16q (P = 0.029) with non-M 0 stage.
The correlation between number of CNAs and age in years was 0.32 (P = 0.06). None of the three infants had a CNA; the other young patient (2.9 years) had two CNAs. The mean survival of the three infants was 189 days.
i(17)(q10) was associated with the poor-risk group (P = 0.01). All five patients with i(17)(q10) were in the poor-risk group and all died. A multivariate Cox regression analysis was used to assess the significance of i(17)(q10) controlled for important prognostic factors, specifically, age (<3 versus z3), M stage (M 0 versus non-M 0 ), and residual tumor (<1.5 versus >1.5 mL). Based on these factors, increased risk was observed for those with i(17)(q10) with respect to OS (P = 0.004; relative risk, 11.1; 95% confidence interval, 1.9-65.7) as well as EFS (P = 0.011; relative risk, 7.7; 95% confidence interval, 1.4-41.8). In addition, analyses of OS and EFS comparing only the poor-risk patients with and without i(17)(q10) showed significantly worse outcome for the poor-risk patients with i(17)(q10) for both OS (P = 0.024) and EFS (P = 0.034). Five-year OS and EFS rates are 75 F 15% for the poor-risk patients without i(17)(q10) compared with 20 F 18% for those with i(17)(q10) (Fig. 3) . Thus, even poor-risk patients had reasonable outcomes if their tumors did not have i(17)(q10).
Unsupervised clustering. Cluster analysis is an appropriate method to evaluate relatively small numbers of cases when large amounts of data are associated with each case. Unsupervised clustering groups cases with similar data patterns. We evaluated cases for similarities in genetic aberrations. The unsupervised method does not involve predetermined reference vectors; thus, there is no a priori knowledge of the patterns that are generated. However, the results of unsupervised clustering do not provide a measure of statistical significance.
Unsupervised clustering sorted the 35 study patients into four subgroups (A-D; Fig. 4 ). The 10 tumors in group A tended to have À8, À11p, À11q, À17p, ÀX, and +7 and +17q. Four of the five i(17)(q10) patients were clustered into group A. Five of the group A patients were standard risk, with one having died. Four of the five poor-risk patients died, and all four had i(17)(q10). Thus, the standard-risk group A patients tended to have more favorable outcomes than the poor-risk group A patients.
Group B consisted of three tumors that tended to have À14q, À15q, À17p, ÀX, and +17. These patients tended to have z5 losses and V3 gains. Two of the three group B patients were standard risk, and the third patient's risk group status was unknown. Both standard-risk patients are alive (one was lost to follow up), whereas the unknown risk patient died.
Group C consisted of 16 tumors with few CNAs. Thirteen of 16 tumors had V3 CNAs. Five had no CNAs, including the three infant patients. There were eight standard-risk patients (seven alive), five poor-risk (four alive), and three infants (all died). The one poor-risk patient who died had +1q, whereas the other poor-risk patients did not gain 1q.
The six tumors in group D are characterized primarily by À9 and À16, and +1q, +6, +7q, and +8. Two of the three standard-risk group D patients died, and two of the three poor-risk patients also died [one of whom had i(17)(q10)]. Both the standard-risk and poor-risk patients who survived had +1q and À9q.
Supervised analysis. Supervised analysis by SAM provides a statistical measure of data associated with references such as gender, M stage, and risk group. The statistical significance is expressed as the q value, which is analogous to the P value, in that the q value decreases with the likelihood that the measurement is actually null. Suppose that features with qs V 1.5% are called significant in some genome-wide test of significance. This results in a false-discovery rate of 1.5% among the significant features.
We used clinical criteria such as gender, M 0 versus non-M 0 stage, risk group, overall outcome, and outcome within risk groups to sort patients into groups for SAM analysis. We found that 14q31.1-q31.3 and X were associated with patient gender (q = 2.1, FDR = 2.1). Three female patients had À14q31.1-q31.3, whereas one male patient had gain of this region. Although the female patients had other areas of loss on 14q (Table 2) , only 14q31.1-q31.3 was associated with gender. Six female patients had ÀX, whereas only two male patients had ÀX. Five of the six female patients with ÀXp22.33-q28 survived, whereas the one who died had i(17)(q10). Both male patients died and one had i(17)(q10). All of the patients with CNAs of 14q31.1-q31.3 survived. Several chromosome regions tended towards associations with EFS. Two patients with +8p12-q24.3 died [one had i(17)(q10)], whereas four patients with À8p12-q24.3 survived (q = 5.1, FDR = 2.6). In addition, six survivors had ÀYq11.1-12, whereas none of the patients who died had this loss (q = 5.1, FDR = 2.6).
Unsupervised clustering identified and ranked multiple chromosome regions distinguishing between the subgroups, including 6p, 7p, 7q, 8, 11p, 14q, 15q, 17q , and X. CNAs that best characterized group A by SAM analysis included +7, À8, À11p, +17q, and ÀX. CNAs characteristic for group B included À14q, À15q, +17q, and ÀX. There were no CNAs that distinguished group C patients. Group D CNA features included +6p, +7q, and +8. Thus, SAM identified the specific Research. CNAs that determined the medulloblastoma patient genetic subgroups.
SAM did not detect CNAs that distinguished groups by stage, risk group, survival, or age (q > 5) or that distinguished between survivors and nonsurvivors within the standard-risk (q= 81, FDR = 56.5) or poor-risk groups (q = 31, FDR = 21).
Discussion
To our knowledge, this was the first study that evaluated the relationship of medulloblastoma survival to CGH. i(17)(q10) was associated with shorter OS (P = 0.03) and EFS (P = 0.04). Five of 13 poor-risk patients had i(17)(q10) (three with disseminated disease and two with postsurgical residual tumors >1.5 mL), all of whom died. Six of the eight poor-risk patients without i(17)(q10) were alive at last contact. Thus, most poorrisk patients had favorable outcomes if their tumors did not have i(17)(q10). A comparison based on only the poor-risk patients showed significant differences in OS (P = 0.024) and EFS (P = 0.034) between patients with and without i(17)(q10). i(17)(q10) has a significant independent negative effect on outcome, and this effect is not driven by the poor-risk classification. Thus, patient outcome, particularly among poor-risk patients, was better determined with genetic criteria compared with clinical criteria alone.
Although the clinical risk group classification is helpful in identifying medulloblastoma patients with worse prognosis, it is known that patients within risk groups have widely varying outcomes. The 5-year OS for poor-risk patients without i(17)(q10) in our study was 75%, which is better than the study group as a whole (63%). Thus, poor-risk classification does not necessitate poor outcome. Furthermore, none of these cases were in the infant risk group, which has a poor prognosis regardless of stage of disease or extent of resection. Because there were relatively few tumors with i(17)(q10), we cannot form a definitive conclusion concerning the role of i(17)(q10) in outcome.
i (17)(q10) is the most common chromosome aberration in childhood medulloblastoma, occurring in f25% to 35% of cases (17 -21) . Previous analysis suggests it is not an independent prognostic factor (22 -24) . However, prior studies suggest that poor-risk patients with i(17)(q10) tend toward poor rather than favorable outcomes. For example, Gilbertson et al. described 10 poor-risk medulloblastoma patients with i(17)(q10), six of whom died before study completion (24) . Three of the four surviving poor-risk i(17)(q10) patients had desmoplastic medulloblastomas, which reportedly have better outcomes than classic medulloblastomas (20, 25) . Only one of the six poor-risk patients who died had a desmoplastic medulloblastoma. In the study by Nicholson et al., four of seven poor-risk i(17)(q10) patients died. One surviving patient in this group had a desmoplastic medulloblastoma, and another had only survived 0.3 years from treatment until the end of the study (20) . None of the i(17)(q10) patients who died had desmoplastic medulloblastomas. It is not clear why i(17)(q10) has a negative effect on outcome among poor-risk cases.
Chromosome 17p, the most frequently deleted chromosome (29%) in our study, was not associated with OS (P = 0.14) or EFS (P = 0.15). However, the role of 17p deletion as a prognostic factor remains unclear. Cogen and McDonald reported that deletions on 17p in standard-risk medulloblastoma patients were associated with poor outcome (P = 0.022; ref. 26) , whereas Biegel et al. found that 17p deletion tended to associate poor outcome but the trend was not statistically significant (27) . Emadian et al. found no association between 17p deletion and survival (28) . Eberhart et al. reported that all seven cases with 17p loss in their study occurred in anaplastic medulloblastomas, four of whom died within 27 months from diagnosis (29) . Thus, 17p loss may be associated with more biologically aggressive medulloblastomas.
The second most common aberration in medulloblastomas is gain of the entire chromosome 7. Although the frequency of i(17)(q10) in this study (14%) was lower than previously, the frequency of +7 (23%) was comparable with the reported rate of 25% (18 -21, 30 -33) . +7 was not associated with OS (P = 0.26) or EFS (P = 0.25) in our study. +7 is a frequent aberration in glioblastomas (34) and is associated with worse survival in anaplastic astrocytoma patients (35) , but its significance in medulloblastomas is unknown.
Deletion of 9q tended to associate with improved OS and EFS (P = 0.07). Four of the five patients were standard risk and all five were alive at last contact. This observation may be related to observations associating mutations of the PTCH gene (9q22.3) with desmoplastic medulloblastomas (36, 37) . Pediatric patients with desmoplastic medulloblastomas may have more favorable outcomes than classic medulloblastoma patients (20, 25) . There were four patients in our study (two standard and two poor risk) who had non-nodular desmoplastic medulloblastomas; all four were alive at last contact.
CNA number tended to associate with age <3 (P = 0.06). Four patients were <3 years of age, three of whom were infants. None of these three tumors had CNAs, and none survived longer than 285 days from study entry. The fourth was a poorrisk patient who had two CNAs and survived. Medulloblastomas in infants may represent a genetic subset distinct from medulloblastomas in older children.
One tumor had amplification of 5p15.1-p15.3. Amplification at 5p15 was reported in patients with good outcomes (18, 33) . Amplification of the hTERT gene (chromosome 5p15.33), which encodes the catalytic protein subunit of telomerase and is associated with carcinogenesis, has been reported in 38% of medulloblastomas (38) . In our study, the patient with 5p amplification was still alive over 12 years after diagnosis.
Unsupervised clustering sorted our study patients into four subgroups. Several CNAs were identified as defining the various subgroups. Group C patients were characterized by few CNAs. Because unsupervised clustering is a qualitative rather than quantitative analysis, statistical correlations could not be made with regard to associations between particular CNAs and their subgroups or CNAs to outcome.
SAM analysis quantitatively validated the results of our unsupervised cluster analysis. CNAs that significantly distinguished between the subgroups were also identified by unsupervised clustering. There were also CNAs that distinguished between gender (female patients tended to have À14q31.1-q31.3 and ÀX). Given the small number of patients, definitive conclusions should not be made regarding the significance of these particular CNAs. However, the application of SAM to further define genetic medulloblastoma subgroups is appropriate and useful for future studies.
Conclusions
Our study had the largest reported number of medulloblastoma cases with CGH and outcome data to our knowledge. i(17)(q10) is associated with poor outcome independent of risk group classification, and low number of CNAs tends to be associated with poor outcome. Medulloblastomas in infants may be a genetically distinct subset from those in older children. Our results showed that medulloblastomas are genetically heterogeneous tumors. Genetic aberrations define subsets of medulloblastomas beyond clinical criteria and seem to have a stronger predictive value for outcome compared with clinical criteria alone, particularly for poor-risk patients. In our study, poor-risk patients without i(17)(q10) had significantly improved OS and EFS compared with poor-risk i(17)(q10) patients. As noted in Case Selection, genetic analysis can help identify histologically misdiagnosed tumors. There was a strong concordance in our study between the results of unsupervised cluster analysis and supervised analysis with SAM. These analyses suggest specific chromosomes are important for determining medulloblastoma patient subsets, but the data must be interpreted cautiously until larger studies verify these results. Subsequent studies should include a larger number of patients analyzed with array CGH, which has significantly higher resolution than standard CGH, and should employ not only standard statistical methods but also unsupervised cluster analysis and SAM. Future studies that accrue sufficient patient numbers may confirm specific CNAs as prognostic factors for childhood medulloblastoma patients. These results combined with gene expression analyses and current clinical stratification criteria may lead to the development of a highly accurate predictive model for medulloblastoma behavior and outcome.
